MARÍA AZUCENA
ESPARIS OGANDO
Investigadora en el periodo 1995-1996
![Foto de Alberto](/img/nophoto.png)
Alberto
Ocaña
Publicaciones en las que colabora con Alberto Ocaña (10)
2020
-
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cancer Letters, Vol. 491, pp. 50-59
2019
-
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
Frontiers in Immunology, Vol. 10
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
2016
-
Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
Oncotarget, Vol. 7, Núm. 29, pp. 45042-45051
-
Targeting the EGF/HER ligand-receptor system in cancer
Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898
2014
-
Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer
Oncogene, Vol. 33, Núm. 2, pp. 148-156
-
Therapeutic potential of ERK5 targeting in triple negative breast cancer
Oncotarget, Vol. 5, Núm. 22, pp. 11308-11318
2009
2008
-
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
Annals of Oncology, Vol. 19, Núm. 11, pp. 1860-1869
2007
-
Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer
Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2656-2663